계명대학교 의학도서관 Repository

미숙아 빈혈에서 Recombinant Human Erythropoietin의 투여용량에 따른 효과

Metadata Downloads
Author(s)
김대훈김천수박근수김명성이상락
Keimyung Author(s)
Kim, Chun SooPark, Geun SooKim, Myung SungLee, Sang Lak
Department
Dept. of Pediatrics (소아청소년학)
Institute for Medical Science (의과학 연구소)
Journal Title
Keimyung Medical Journal
Issued Date
1996
Volume
15
Issue
4
Keyword
Recombinant human erythropoietin(rHuEPO)Anemia of prematurity.
Abstract
Anemia of prematurity is a major problem in caring of preterm babies, and up to recent days transfusion is a routine therapy for this disease. Transfusion causes various complications such as blood-borne viral infections, graft-versus-host reaction, hyperkalemia. Recently, the use of recombinant human erythropoietin(rHuEPP) is an alternative therapy for anemia of prematurity, but optimal dosage of rHuEPO is not uncertain. So, we conducted this study to determine the optimal dosage of rHuEPO in reducing postnatal transfusion and to assess the safety of rHuEPO in prematurity.
Four groups of healthy premature infants of less than 34 weeks' gestation with birth weight less than 1.6kg were treated without rHuEPO(control group, n=6) or with rHuEPO:Epo-600 group(n=10) received 600 U/kg/week;Epo-900group(n=10), 900 U/kg/week; Epo-1,200 group(n=10), 1,200 U/kg/week, who were admitted to the Neonatal intensive care unit, Dong-San Medical Center, Keimyung University during the period of 2 years from Jan. 1994 to Dec. 1995. All rHuEPO-treated infants were given iron supplements, and all infants received folic acid and vitamin E supplements.
The following results were obtained.
1) The mean birth weight, gestational age, age of therapy onset, initial hemoglobin and reticulocyte count showed similar distribution in all groups.
2) The reticulocyte count was significantly higher in Epo-1,200 group at 1 week, and all rHuEPO groups at 4 weeks after therapy than that of control group(P<0.05).
3) The mean serum iron level was lower in EPO-treated g개up than that of control group after therapy, but statistically not significant. The mean serum ferritin level was significantly lower in Epo-1,200 group than that of control group(P<0.05)
4) The blood erythropoietin level was similar in all groups during therapy.
5) Phlebotomy volume was similar in all groups, but high-does group(Epo-900, Epo-1,200) received significantly less transfusions than control and Epo-600 group(P<0.05).
6) Any side effects related rHuEPO therapy were not observed in all treated group.
In conclusion, higher dosage(more than 900 U/kg/week) of rHuEPO therapy is safe and effective in reducing the need for blood transfusion.
Alternative Title
The Dosage Related
Effect of Recombinant Human Erythropoietin in Anemia of Prematurity
Keimyung Author(s)(Kor)
김천수
박근수
김명성
이상락
Publisher
Keimyung University School of Medicine
Citation
김대훈 et al. (1996). 미숙아 빈혈에서 Recombinant Human Erythropoietin의 투여용량에 따른 효과. Keimyung Medical Journal, 15(4), 334–341.
Type
Article
URI
https://kumel.medlib.dsmc.or.kr/handle/2015.oak/14994
Appears in Collections:
2. Keimyung Medical Journal (계명의대 학술지) > 1996
1. School of Medicine (의과대학) > Dept. of Pediatrics (소아청소년학)
3. Research Institutues (연구소) > Institute for Medical Science (의과학연구소)
Authorize & License
  • Authorize공개
Files in This Item:

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.